Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.

Autor: Donnez J; Société de Recherche pour l'infertilité, Catholic University of Louvain, Brussels, Belgium., Taylor HS; Yale University School of Medicine, New Haven, CT, USA., Stewart EA; Division of Reproductive Endocrinology, Mayo Clinic and Mayo Clinic Alix School of Medicine, Rochester, MN, USA., Bradley L; Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH, USA., Marsh E; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, USA., Archer D; Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA, USA., Al-Hendy A; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA., Petraglia F; Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Watts N; Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA., Gotteland JP; ObsEva, Geneva, Switzerland., Bestel E; ObsEva, Geneva, Switzerland., Terrill P; Cytel, London, UK., Loumaye E; ObsEva, Geneva, Switzerland., Humberstone A; ObsEva, Geneva, Switzerland., Garner E; Ferring Pharmaceuticals, Parsippanny, NJ, USA. Electronic address: elizabeth.garner@ferring.com.

Publikováno v: Lancet (London, England) [Lancet] 2022 Sep 17; Vol. 400 (10356), pp. 896-907.

Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study.

Autor: Donnez J; Université Catholique de Louvain, Louvain, Belgium; Société de Recherche pour l'infertilité (SRI), Brussels, Belgium. Electronic address: Jacques.donnez@gmail.com., Donnez O; Polyclinique Urbain V (ELSAN Group), Institut du Sein et de Chirurgie Gynécologique d'Avignon, Avignon, France., Brethous M; ObsEva SA, Geneva, Switzerland., Bestel E; ObsEva SA, Geneva, Switzerland., Garner E; ObsEva Inc, Boston MA, USA., Charpentier S; ObsEva SA, Geneva, Switzerland., Humberstone A; ObsEva SA, Geneva, Switzerland., Loumaye E; ObsEva SA, Geneva, Switzerland.

Publikováno v: Reproductive biomedicine online [Reprod Biomed Online] 2022 Jan; Vol. 44 (1), pp. 200-203. Date of Electronic Publication: 2021 Oct 03.

A placebo-controlled, randomized, double-blind study of pregnancy and live birth rates after single oral administration of a novel oxytocin antagonist, nolasiban, prior to embryo transfer

Autor: Tournaye, H., Humberstone, A., Lecomte, V., Terrill, P., Pierzynski, P., Loumaye, E.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3848::95b21a62e9e5907f34ebceff33b5f573
https://biblio.vub.ac.be/vubir/a-placebocontrolled-randomized-doubleblind-study-of-pregnancy-and-live-birth-rates-after-single-oral-administration-of-a-novel-oxytocin-antagonist-nolasiban-prior-to-embryo-transfer(8da6b2f1-c1f1-42b7-b7bb-039fc2944c85).html

Ulipristal acetate versus leuprolide acetate for uterine fibroids

Autor: Donnez J., Tomaszewski J., Vaszquez F., Bouchard P., Lemieszczuk B., Barò F., Nouri K., Selvaggi L., Sodowski K., Bestel E., Terrill P., Osterloh I., Loumaye E., Barlow D. H., Barri P. N., Bergeron C., Bornstein J., Caraco Y., Carmona F., Caruso A., Diedrich K., Donnez O., Fauser B. C., Ferenczy A., Gilabert J., Giuliani A., Glezerman M., Goettker Schnetmann W., Hillemanns P., Huber J., Jimenez J. S., Kay R., Kiesel L., Kotarski J., Layani L., Mannering M., Marshall J., Martinez S., McPherson K., Melis G. B., Milani R., Morris E., Nisolle M., Palacios S., Parrilla J. J., Paul N. W., Pawlaczyk A., Pellicer A., Perino A., Vazquez F., Williams A. R., de Ziegler D., NAPPI, CARMINE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3730::a37cbb7cf503500f5ffb3504438a6530
http://hdl.handle.net/11588/485043

Recombinant Human Luteinizing Hormone is as effective as, but safer than urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro procedures: results of a multicenter double-blind study

Autor: Engrand P, Arguinzoniz, Piazzi A, Loumaye E, Devroey P, Smith J, Andersen AN, Frydman, Hedon B, Hugues JN, Roulier R, Salat Baroux J, Homburg R, Shoham Z, Barash A, Palermo R, Flamigni C, Schoemaker J, Te Velde E. R, Braat D, Hamberger L, Germond M, Imthurn B, Barlow DH, Brisden P, Fleming R, Hull M, Lockwood G, Templeton A, Yates R., PORCU, ELEONORA

n a prospective, comparative, dose-finding study, the minimal effective dose of recombinant human LH (rhLH) required to induce final follicular maturation and early luteinization in patients undergoing in vitro fertilization and embryo transfer was d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::695efd63ea3bf97299c8a678f96ae5dd
http://hdl.handle.net/11585/121364